UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Edward Garon, M.D.

Specialty:

Hematology/Oncology

General Information:

Gender:	Male
Language(s):	English

Affiliation(s):

H.S. Clinical Assistant Professor, Department of Medicine, Hematology/Oncology

Director of Thoracic Oncology Program

Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Santa Monica - UCLA Medical Center and Orthopaedic Hospital

Ronald Reagan UCLA Medical Center

Education:

Fellowship	Hematology/Oncology, UCLA School of Medicine, 2003 - 2006
Residency:	Internal Medicine, University of Chicago Hospitals, 2000 - 2002
Internship:	Internal Medicine, University of Chicago Hospitals, 1999 - 2000
Medical Degree:	M.D., Washington University School of Medicine, 1999

Certification(s):

Medical Board Certification(s):	Hematology and Oncology, American Board of Internal Medicine, 2006 Medical Oncology, American Board of Internal Medicine, 2006 Internal Medicine, American Board of Internal Medicine, 2002

Contact Information:

Phone:	(310) 586-2098 Office (310) 829-5471 Patient referrals
Email:	egaron@mednet.ucla.edu

Practice Information:

Clinical Interest(s):	Thoracic

Scientific Interest(s):

Dr. Edward Garon's research focuses on developing novel therapies for cancers of the chest (most frequently lung cancer). In his laboratory work, he focuses on determining molecular subtypes of these common cancers. He then evaluates the effects of novel therapeutics against these different subtypes.

In addition to laboratory research, Garon is the principal investigator on a wide range of clinical trials. The ultimate goal of his work is to determine subgroups of lung cancer patients most likely to respond to certain therapies and then translate those observations into rational clinical trials.

Selected Cancer-Related Publications:

Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB. Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung. J Thorac Oncol. 2012 Oct;7(10):1618-1621.

Kurita K, Garon EB, Stanton AL, Meyerowitz BE. Uncertainty and psychological adjustment in patients with lung cancer. Psychooncology. 2012 Aug 13. doi: 10.1002/pon.3155. [Epub ahead of print]

Garon EB, Cao D, Alexandris E, John WJ, Yurasov S, Perol M. A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design. Clin Lung Cancer. 2012 Nov;13(6):505-9. doi: 10.1016/j.cllc.2012.06.007. Epub 2012 Jul 31.

Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011 Mar 1;17(5):1131-9. doi: 10.1158/1078-0432.CCR-10-1220. Epub 2011 Jan 10.

Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 2010 Jul;9(7):1985-94. Epub 2010 Jun 29.